Premium
Immunohistochemical expression of somatostatin receptor subtypes 2 and 5 in colorectal cancer
Author(s) -
Evangelou Ioulia,
Petraki Constantina,
Msaouel Pavlos,
Scorilas Andreas,
Sdrolia Eleni,
Padazi Georgia,
Koborozos Vassilios,
Koutsilieris Michael
Publication year - 2012
Publication title -
european journal of clinical investigation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.164
H-Index - 107
eISSN - 1365-2362
pISSN - 0014-2972
DOI - 10.1111/j.1365-2362.2012.02648.x
Subject(s) - somatostatin receptor , immunohistochemistry , colorectal cancer , somatostatin , medicine , somatostatin receptor 2 , rectum , metastasis , cancer , pathology , oncology , gastroenterology
Eur J Clin Invest 2012; 42 (7): 777–783 Abstract Background To determine the immunohistochemical expression levels of the somatostatin receptor subtypes 2 and 5 (Sst2 and Sst5) in patients with colorectal cancer (CRC) and to investigate the association of Sst2 and Sst5 expression with clinicopathological parameters. Materials and methods A retrospective analysis of formalin‐fixed and paraffin‐embedded CRC surgical specimens from 81 patients assessed by immunohistochemistry for Sst2 and Sst5 expression. Results Sst2 and Sst5 expression levels showed significant, negative association with CRC invasion and liver metastasis ( P values < 0·05) while Sst2 also showed significantly increased expression in lower‐grade tumours as well as in tumours located in the rectum ( P values < 0·05). Patients with CRC expressing either Sst2 or Sst5 had significantly longer survival rates ( P values < 0·05), although Sst expression was not found to be an independent predictor of survival after controlling for other known prognostic clinicopathological variables ( P values > 0·05). Conclusions The present data confirm the relationship of Sst2 and Sst5 expression levels with reduced tumour aggressiveness.